120 related articles for article (PubMed ID: 35093762)
1. Global DNA methylation changes in treated and untreated MS patients measured over time.
Brorson IS; Eriksson AM; Høgestøl E; Leikfoss IS; Harbo HF; Berge T; Vitelli V; Bos SD
J Neuroimmunol; 2022 Mar; 364():577808. PubMed ID: 35093762
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA methylation profiles indicate CD8+ T cell hypermethylation in multiple sclerosis.
Bos SD; Page CM; Andreassen BK; Elboudwarej E; Gustavsen MW; Briggs F; Quach H; Leikfoss IS; Bjølgerud A; Berge T; Harbo HF; Barcellos LF
PLoS One; 2015; 10(3):e0117403. PubMed ID: 25734800
[TBL] [Abstract][Full Text] [Related]
3. HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence.
Koudriavtseva T; Plantone D; Mandoj C; Giannarelli D; Latini A; Colafigli M; Trento E; Cordiali-Fei P; Pimpinelli F
J Neurovirol; 2017 Feb; 23(1):147-151. PubMed ID: 27431677
[TBL] [Abstract][Full Text] [Related]
4. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Ruhrmann S; Ewing E; Piket E; Kular L; Cetrulo Lorenzi JC; Fernandes SJ; Morikawa H; Aeinehband S; Sayols-Baixeras S; Aslibekyan S; Absher DM; Arnett DK; Tegner J; Gomez-Cabrero D; Piehl F; Jagodic M
Mult Scler; 2018 Sep; 24(10):1288-1300. PubMed ID: 28766461
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
8. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
9. Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis.
Graves MC; Benton M; Lea RA; Boyle M; Tajouri L; Macartney-Coxson D; Scott RJ; Lechner-Scott J
Mult Scler; 2014 Jul; 20(8):1033-41. PubMed ID: 24336351
[TBL] [Abstract][Full Text] [Related]
10. Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.
Rhead B; Brorson IS; Berge T; Adams C; Quach H; Moen SM; Berg-Hansen P; Celius EG; Sangurdekar DP; Bronson PG; Lea RA; Burnard S; Maltby VE; Scott RJ; Lechner-Scott J; Harbo HF; Bos SD; Barcellos LF
PLoS One; 2018; 13(10):e0206511. PubMed ID: 30379917
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
12. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patients.
Kiselev I; Danilova L; Baulina N; Baturina O; Kabilov M; Boyko A; Kulakova O; Favorova O
Mult Scler Relat Disord; 2022 Apr; 60():103714. PubMed ID: 35245816
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.
Spadaro M; Montarolo F; Perga S; Martire S; Brescia F; Malucchi S; Bertolotto A
Clin Immunol; 2017 Aug; 181():83-88. PubMed ID: 28642148
[TBL] [Abstract][Full Text] [Related]
15. Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis.
Hintzen RQ; Pot K; Paty D; Oger J
Acta Neurol Scand; 2000 Jan; 101(1):57-60. PubMed ID: 10660154
[TBL] [Abstract][Full Text] [Related]
16. The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis.
Okuda Y; Okuda M; Apatoff BR; Posnett DN
J Neurol Sci; 2005 Aug; 235(1-2):11-7. PubMed ID: 15972217
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
[TBL] [Abstract][Full Text] [Related]
18. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
[TBL] [Abstract][Full Text] [Related]
19. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
[TBL] [Abstract][Full Text] [Related]
20. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
